The Therapeutics Initiative Blog brings you news and information from the world of therapeutics. Bookmark this page to see our frequently refreshed content.
On September 5, 2019, British Columbia announced a new policy to switch from originator to biosimilar infliximab for patients with inflammatory bowel diseases (IBD). Subsequently,
The results of many clinical trials are not publicly reported, or reported only after a long delay. Why? Dr. Richard Morrow explored the views of trial participants, scientists, an
From the clinicians who brought you the highly acclaimed Best Science Medicine Course; Meds Conference; BS Medicine Podcast; Practical Evidence for Informed Practice (PEIP) Confere
The inaugural live Deprescribing Webinar took place on February 8, 2023. Scroll down to view the video recording. The next Deprescribing Webinar is scheduled for April 19, 2023. &#
When our founding Scientific Director Dr. Jim Wright started the Therapeutics Letter in 1994, our goals included relevance to practicing clinicians, accuracy, brevity, and critical
Dopamine receptor antagonists are a broad class of drugs characterized by their ability to interfere with the natural actions of the neurotransmitter dopamine, typically in brain,
Bringing Best Evidence to Clinicians: Saturday, October 15, 2022 from 08:30-12:20 h, PDT Have you ever considered participating in one of the TI’s annual courses? This year we
On September 14, 2022 the University of British Columbia’s Therapeutics Initiative, an academic service that provides unbiased evidence about drug therapy to prescribers and ph
My name is Ashley Perreault, and I am now starting my third year of medical school at the Northern Ontario School of Medicine, based in Thunder Bay, Ontario, Canada. I have no conf
Medical student questions how Health Canada licensed OxyContin By Jessie Pappin Students at Dalhousie Medical School must pass a mandatory longitudinal course, Research in Medicine